Abstract:The chemokine receptor CXCR4 has become an attractive therapeutic target for HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis. A wide variety of synthetic antagonists of CXCR4 have been developed and studied for a growing list of clinical applications. To compare the biological effects of different antagonists on CXCR4 functions and their common and/or distinctive molecular interactions with the receptor, we conducted head-to-head comparative cell-based biological and mutational analyses of the interactions with CXCR4 of eleven reported antagonists, including HC4319, DV3, DV1, DV1 dimer, V1, vMIP-II, CVX15, LY2510924, IT1t, AMD3100, and AMD11070 that were representative of different structural classes of D-peptides, L-peptide, natural chemokine, cyclic peptides, and small molecules. The results were rationalized by molecular modeling of CXCR4-antagonist interactions from which the common as well as different receptor binding sites of these antagonists were derived, revealing a number of important residues such as W94, D97, H113, D171, D262, and E288, mostly of negative charge. To further examine this finding, we designed and synthesized new antagonistic analogs by adding positively charged residues Arg to a D-peptide template to enhance the postulated charge-charge interactions. The newly designed analogs displayed significantly increased binding to CXCR4, which supports the notion that negatively charged residues of CXCR4 can engage in interactions with moieties of positive charge of the antagonistic ligands. The results from these mutational, modeling and new analog design studies shed new insight into the molecular mechanisms of different types of antagonists in recognizing CXCR4 and guide the development of new therapeutic agents.

Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas

Clinical Significance of Chemokine Receptor Antagonists

The Role and Therapeutic Targeting of CCR5 in Breast Cancer

CCR5 is a potential therapeutic target for cancer

Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance

The CCL5/CCR5 Axis in Cancer Progression

CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma

Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment

Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV.

The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment

CXC Chemokine Receptors in the Tumor Microenvironment and an Update of Antagonist Development

Advances of CCR5 antagonists: From small molecules to macromolecules

CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

A review on CXCR4/CXCL12 axis in oncology: No place to hide

The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

The Role of Cxc Chemokines and Their Receptors in the Progression and Treatment of Tumors

The Chemical Diversity and Structure-Based Evolution of Non-Peptide CXCR4 Antagonists with Diverse Therapeutic Potential.

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Chemokines and Chemokine Receptors Required for Optimal Responses to Anticancer Chemotherapy.

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer